Biosimilars

The Humira biosimilar is a tumor necrosis factor (TNF) blocker and was approved by the FDA in 2021.

These medications join adalimumab-atto, which launched on January 31.

Boehringer Ingelheim’s Cyltezo is the first and only FDA-approved interchangeable biosimilar to adalimumab.

Although biosimilars have been introduced with the aim of competing with expensive biologic therapies, their adoption has been more gradual than expected.

A study found that pharmacists possessed moderate to low knowledge scores when it came to statements tackling biosimilars.

The Act4Biosimilars Action Plan aims to highlight key challenges preventing patient access to biosimilars and outline steps to help overcome them.

Hesitation from patients and providers to switch to an infliximab biosimilar may not be necessary, new study finds.

At least 6 adalimumab biosimilars are set to launch in July 2023.

Yusimry (adalimumab-aqvh) is 1 of 9 FDA-approved adalimumab biosimilars and is a low-concentration, citrate-free product.

Years of steady price increases have made access to the essential medicine more difficult for millions of Americans with diabetes.

Juliana Reed, executive director of the Biosimilars Forum, discussed the impact of market dynamics and changing pricing structures during a presentation at the 2023 Asembia Specialty Pharmacy Summit.

88% of surveyed payers said interchangeability will have the biggest impact on adoption.

The Inflation Reduction Act boosted the Medicare payment for biosimilars from the standard average sales price plus 6% to 8%.

As more adalimumab biosimilars are poised to enter the market, manufacturers, payers, and patient advocates are preparing to navigate potentially turbulent waters.

The drug, manufactured by Sandoz, will treat conditions including osteoporosis in postmenopausal women

The new report reviewed the potential impact of biosimilars across multiple specialties.

The launch of Amgen's adalimumab biosimilar Amjevita was just the start of a wave of biosimilars to treat autoimmune diseases.

The Biologics License Application of a proposed biosimilar of denosumab, a drug that could treat several bone diseases and issues, has been accepted by the FDA.

Adalimumab-atto was first approved by the FDA in 2016.

As many as 10 Humira biosimilars may be on the US market before 2023 is over. AbbVie has taken several steps to protect its revenues, including the launches of Skyrizi and Rinvoq.

Take a look back at our most popular biosimilars coverage for 2022.

Biosimilar medications stand to significantly increase cost savings for patients.

From biosimilars to artificial intelligence, these are the trends poised to take community pharmacy by storm.

The authors noted that the proportion of patients losing fewer than 15 letters from the baseline BCVA score in the study eye was comparable between the two groups.

The review focused on Remicade (infliximab) and Enbrel (etanercept). The annualized discontinuation rate was 21% among patients who had undergone nonmedical switching to biosimilars. However, the rates were similar to those found in some separate analyses of patients on reference biologics.

Several provisions in the law are designed to protect and foster the biosimilar market. But some representatives of the sector see CMS drug price negotiation as a threat to profit margins.

Some companies are using the interchangeability designation as a marketing ploy.

Although further studies are needed to confirm the long-term effects, recent studies have shown the infliximab biosimilar to be a safe, effective, and cost reducing treatment for inflammatory bowel diseases.

New research should give expectant mothers some peace of mind.

Humira may face competition from multiple generics next year, but an octet of other biologics may also see competition this decade.